Trius Therapeutics Inc (TSRX.OQ)
13.81USD
1:15pm EDT
$-0.29 (-2.09%)
$14.10
$13.80
$13.89
$13.75
273,626
328,056
$14.16
$4.41
About
Overall
| Beta: | -- |
| Market Cap (Mil.): | $675.00 |
| Shares Outstanding (Mil.): | 47.87 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| TSRX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 37.93 | 37.76 |
| EPS (TTM): | -1.56 | -- | -- |
| ROI: | -77.67 | 19.48 | 18.76 |
| ROE: | -77.67 | 20.17 | 19.59 |
Cubist to pay up to $1.6 billion for two antibiotics makers
- Cubist Pharmaceuticals Inc has agreed to pay up to $1.6 billion for Trius Therapeutics Inc and Optimer Pharmaceuticals Inc, expanding its heft in antibiotics at a time when the number of drug-resistant viruses are on the rise.
UPDATE 2-Cubist to pay up to $1.6 bln for two antibiotics makers
* Cubist sees the sum of both deals to be accretive in 2015
Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 billion
- Cubist Pharmaceuticals Inc said it would buy Trius Therapeutics Inc and Optimer Pharmaceuticals Inc for up to $1.62 billion to boost its antibiotics portfolio.
CORRECTED-Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 bln
(Corrects paragraphs 2 and 3 to say the per-share offers include contingency payments)
BRIEF-Trius Therapeutics up in premarket after tedizolid study results
NEW YORK, March 25 - Trius Therapeutics Inc : * Up 6.6 percent to $7.45 in premarket after tedizolid study results
Competitors
| Price | Change | |
|---|---|---|
| Abbott Laboratories (ABT.N) | $37.00 | +0.37 |
| Cubist Pharmaceuticals Inc (CBST.OQ) | $64.15 | +1.82 |
| Pfizer Inc. (PFE.N) | $29.04 | -0.19 |
| Forest Laboratories, Inc. (FRX.N) | $44.67 | +1.11 |
| AstraZeneca plc (AZN.L) | 3,334.00p | -1.00 |
| Basilea Pharmaceutica AG (BSLN.S) | CHF74.55 | -0.45 |
| Sanofi SA (SASY.PA) | €76.85 | -3.32 |
| Theravance Inc (THRX.OQ) | $37.84 | -0.72 |
| Astellas Pharma Inc (4503.T) | ¥5,340 | +90.00 |
| The Medicines Company (MDCO.OQ) | $31.42 | +0.52 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Pechala's Reports
|
$25.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

